Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COEP NASDAQ:KPTI NYSE:NBY NASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOEPCoeptis Therapeutics$12.51-2.6%$11.48$2.31▼$14.70$61.94M-0.5744,841 shs38,599 shsKPTIKaryopharm Therapeutics$6.21-1.9%$5.16$3.51▼$16.95$54.89M0.35191,091 shs79,538 shsNBYNovaBay Pharmaceuticals$2.41+4.8%$1.07$0.45▼$4.44$14.04M0.622.55 million shs1.35 million shsSTTKShattuck Labs$1.75-12.9%$0.96$0.69▼$3.95$96.29M1.641.60 million shs844,100 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOEPCoeptis Therapeutics-2.65%-2.49%+13.11%+48.93%+251.80%KPTIKaryopharm Therapeutics-1.90%-12.29%+64.72%+42.43%-42.89%NBYNovaBay Pharmaceuticals+4.78%-10.07%+301.00%+274.46%+428.51%STTKShattuck Labs-12.94%+36.72%+136.74%+63.55%-54.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOEPCoeptis Therapeutics$12.51-2.6%$11.48$2.31▼$14.70$61.94M-0.5744,841 shs38,599 shsKPTIKaryopharm Therapeutics$6.21-1.9%$5.16$3.51▼$16.95$54.89M0.35191,091 shs79,538 shsNBYNovaBay Pharmaceuticals$2.41+4.8%$1.07$0.45▼$4.44$14.04M0.622.55 million shs1.35 million shsSTTKShattuck Labs$1.75-12.9%$0.96$0.69▼$3.95$96.29M1.641.60 million shs844,100 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOEPCoeptis Therapeutics-2.65%-2.49%+13.11%+48.93%+251.80%KPTIKaryopharm Therapeutics-1.90%-12.29%+64.72%+42.43%-42.89%NBYNovaBay Pharmaceuticals+4.78%-10.07%+301.00%+274.46%+428.51%STTKShattuck Labs-12.94%+36.72%+136.74%+63.55%-54.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOEPCoeptis Therapeutics 0.00N/AN/AN/AKPTIKaryopharm Therapeutics 2.80Moderate Buy$34.00447.50% UpsideNBYNovaBay Pharmaceuticals 3.00Buy$0.85-64.73% DownsideSTTKShattuck Labs 2.86Moderate Buy$4.00128.57% UpsideCurrent Analyst Ratings BreakdownLatest NBY, COEP, KPTI, and STTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025STTKShattuck LabsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$4.008/14/2025STTKShattuck LabsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$4.00 ➝ $2.008/14/2025STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/12/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$42.00 ➝ $25.007/16/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/11/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOEPCoeptis TherapeuticsN/AN/AN/AN/A$1.61 per shareN/AKPTIKaryopharm Therapeutics$145.24M0.37N/AN/A($22.10) per share-0.28NBYNovaBay Pharmaceuticals$9.78M1.44N/AN/A$4.25 per share0.57STTKShattuck Labs$5.72M14.65N/AN/A$1.67 per share1.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOEPCoeptis Therapeutics-$10.88M-$5.80N/A∞N/AN/A-201.73%-108.46%N/AKPTIKaryopharm Therapeutics-$76.42M-$14.59N/AN/AN/A-90.02%N/A-84.28%11/4/2025 (Estimated)NBYNovaBay Pharmaceuticals-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/ASTTKShattuck Labs-$75.41M-$1.21N/AN/AN/AN/A-81.80%-71.46%11/13/2025 (Estimated)Latest NBY, COEP, KPTI, and STTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025COEPCoeptis TherapeuticsN/A-$1.17N/A-$1.17N/A$0.20 million8/14/2025Q2 2025STTKShattuck Labs-$0.25-$0.24+$0.01-$0.24N/AN/A8/11/2025Q2 2025KPTIKaryopharm Therapeutics-$3.80-$4.32-$0.52-$4.32$37.92 million$37.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOEPCoeptis TherapeuticsN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/ANBYNovaBay PharmaceuticalsN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOEPCoeptis Therapeutics0.020.830.83KPTIKaryopharm TherapeuticsN/A0.990.94NBYNovaBay PharmaceuticalsN/A1.150.91STTKShattuck LabsN/A10.2510.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOEPCoeptis Therapeutics13.88%KPTIKaryopharm Therapeutics66.44%NBYNovaBay Pharmaceuticals23.25%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipCOEPCoeptis Therapeutics24.25%KPTIKaryopharm Therapeutics2.98%NBYNovaBay Pharmaceuticals0.10%STTKShattuck Labs12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOEPCoeptis Therapeutics24.82 million3.65 millionNot OptionableKPTIKaryopharm Therapeutics3808.67 million8.41 millionOptionableNBYNovaBay Pharmaceuticals305.82 million4.88 millionNot OptionableSTTKShattuck Labs10047.90 million42.16 millionOptionableNBY, COEP, KPTI, and STTK HeadlinesRecent News About These CompaniesQ3 Earnings Estimate for Shattuck Labs Issued By Wedbush46 minutes ago | americanbankingnews.comShattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at WedbushSeptember 10 at 9:36 AM | marketbeat.comShattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Moderate Buy" by AnalystsSeptember 10 at 6:09 AM | marketbeat.comWedbush Initiates Coverage on Shattuck Labs (NASDAQ:STTK)September 10 at 2:01 AM | americanbankingnews.comWedbush Initiates Coverage of Shattuck Labs (STTK) with Outperform RecommendationSeptember 9 at 4:35 AM | msn.comShattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock?September 8 at 6:10 PM | zacks.comWall Street Zen Upgrades Shattuck Labs (NASDAQ:STTK) to "Hold"September 8 at 2:23 AM | marketbeat.comShattuck Labs (NASDAQ:STTK) Stock Rating Upgraded by Wall Street ZenSeptember 7, 2025 | americanbankingnews.comShort Interest in Shattuck Labs, Inc. (NASDAQ:STTK) Grows By 196.4%September 6, 2025 | americanbankingnews.comShattuck Labs (NASDAQ:STTK) Director Orbimed Advisors Llc Purchases 6,306,127 Shares of StockSeptember 3, 2025 | americanbankingnews.comShattuck Labs (NASDAQ:STTK) Director Mona Ashiya Buys 6,306,127 SharesSeptember 3, 2025 | insidertrades.comOrbiMed Advisors buys Shattuck Labs (STTK) shares worth $5.47 millionSeptember 3, 2025 | investing.comAshiya Mona buys Shattuck Labs (STTK) shares worth $5.47 millionSeptember 3, 2025 | investing.comShattuck Labs Closes $103M Private Placement DealAugust 26, 2025 | msn.comShattuck Labs Secures $103 Million in Private Placement to Advance SL-325 for Autoimmune Diseases and Appoints New Board MembersAugust 26, 2025 | quiverquant.comQShattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of DirectorsAugust 26, 2025 | globenewswire.comShattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel DiseaseAugust 22, 2025 | finanznachrichten.deShattuck Labs says IND for SL-325 for treatment of IBD in effectAugust 22, 2025 | msn.comShattuck Labs Reports Q2 2025 Financial ResultsAugust 22, 2025 | msn.comShattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel DiseaseAugust 21, 2025 | globenewswire.comShattuck Labs raises up to $103M to fund therapeutic antibody developmentAugust 19, 2025 | ncbiotech.orgNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBY, COEP, KPTI, and STTK Company DescriptionsCoeptis Therapeutics NASDAQ:COEP$12.51 -0.34 (-2.65%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$12.10 -0.40 (-3.24%) As of 09/10/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.Karyopharm Therapeutics NASDAQ:KPTI$6.21 -0.12 (-1.90%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$6.19 -0.02 (-0.32%) As of 09/10/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.NovaBay Pharmaceuticals NYSE:NBY$2.41 +0.11 (+4.78%) As of 09/10/2025 04:00 PM EasternNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Shattuck Labs NASDAQ:STTK$1.75 -0.26 (-12.94%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$1.74 -0.01 (-0.86%) As of 09/10/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
